Comment from BELLA DERMA AESTHETICS, LLC
AnonymousOpposeIndividual
Summary: A healthcare provider expresses concern that removing specific medications from the 503B bulks list will reduce patient access to affordable, medically supervised treatments. They argue that this action could drive patients toward unregulated online sources and jeopardize patient safety and continuity of care.
As a healthcare provider/practice representative, I am concerned that removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list could significantly reduce patient access to medically supervised treatment. Many patients rely on compounded versions of these medications due to insurance denials, high out-of-pocket costs, medication shortages, or the need for individualized dosing that better supports their treatment goals and tolerability. Eliminating access through regulated 503B outsourcing facilities may not eliminate patient demand; instead, it could drive patients toward unregulated online sources and products obtained without appropriate medical oversight, increasing potential safety risks. While I recognize the FDA's responsibility to ensure medication safety and quality, I encourage careful consideration of the real-world impact on patients who depend on these therapies for chronic weight management and metabolic health. Preserving access through regulated compounding pathways helps maintain continuity of care, supports patient safety, and allows providers to meet the individualized needs of their patients.